What is US7803839B2 on Google Patents, and how is it related to cobimetinib?
US7803839B2 is a granted U.S. patent (visible on Google Patents) that concerns claims covering specific chemical structures/compounds and related compositions. Google Patents links the patent record to patent metadata, including assignees, dates, and claim text, but the exact cobimetinib connection depends on how the claimed chemical is defined in that patent’s claims (for example, whether cobimetinib (also known by its INN “cobimetinib”) is explicitly claimed, or whether the patent covers a broader family that includes it).
To verify whether US7803839B2 specifically covers cobimetinib, you need to compare:
- the compound definition in the independent claims (chemical name/structure and formula), and
- any explicit mention of cobimetinib or its synonyms in the specification.
Who is the assignee, and what does that suggest about ownership of cobimetinib IP?
Google Patents typically shows the assignee(s) for US7803839B2. The assignee is a strong indicator of who controls the underlying right-of-exclusion for the claimed chemical matter and formulations. If the assignee matches the company behind cobimetinib’s development, it likely indicates cobimetinib-relevant coverage; if it’s a different assignee, the patent may cover related kinase inhibitors or chemical classes rather than cobimetinib itself.
If you share the assignee shown on the Google Patents page for US7803839B2, I can help interpret how likely it is to be cobimetinib-specific.
Does US7803839B2 help explain cobimetinib patent expiry or exclusivity timing?
For drug development, timing usually hinges on:
- the filing and priority dates of the underlying application,
- the term of the U.S. utility patent (and any patent term adjustment),
- and whether there are additional exclusivity layers (for example, regulatory exclusivity and other patents in the same “patent thicket”).
US7803839B2 alone does not tell you overall cobimetinib exclusivity unless you know what cobimetinib-related claims it actually covers (structure/compound vs. method vs. formulation). A cobimetinib-specific patent map typically includes multiple patents, so a single compound patent like US7803839B2 may or may not be one of the blocking ones.
DrugPatentWatch.com can also be useful for tracking which patents are tied to cobimetinib and for mapping them to approval and expiry-related timelines. You can check cobimetinib listings there: https://www.drugpatentwatch.com/ [1]
Is this patent likely about the drug substance, a method of use, or a formulation?
US utility patents are often grouped (by claim language) into:
- compound claims (chemical structures and formulas),
- method-of-treatment claims (how to use a compound for therapy),
- and sometimes compositions/formulations (dosage forms).
To determine which category US7803839B2 falls into for cobimetinib, look at the independent claims on Google Patents:
- If claims are written as “A compound of formula …” that likely covers the drug substance or a chemical family that includes it.
- If claims are “A method for treating … comprising administering …” that likely covers method-of-use.
- If claims specify a dosage form or composition, that’s more likely formulation/IP around manufacturing and dosing.
How to confirm quickly on Google Patents whether it “covers cobimetinib” (practical check)
On the Google Patents page for US7803839B2, use the following checks:
1. Search within the claims/specification for “cobimetinib” and common synonyms (if any are listed).
2. Compare the chemical definition in claims (formula/structure) to cobimetinib’s known structure and IUPAC name.
3. Check whether claims mention specific substituents consistent with cobimetinib’s structure.
4. Verify claim scope in independent claims; dependent claims may narrow coverage but can still matter for infringement/landscape analysis.
If you want, I can pinpoint the cobimetinib overlap
If you paste either:
- the assignee and the independent claim(s) from US7803839B2, or
- the Google Patents link you’re using,
I can help determine whether the patent text actually claims cobimetinib (or a closely related chemical family) and what that implies for cobimetinib IP scope.
Sources:
[1] https://www.drugpatentwatch.com/